@Article{,
AUTHOR = {Oleg Shapiro, Karen Jones, Ching Wang, Steve Landas, Gabriel P. Haas},
TITLE = {Risk of post-operative intravesical mitomycin C instillation following transurethral bladder tumor resection},
JOURNAL = {Canadian Journal of Urology},
VOLUME = {13},
YEAR = {2006},
NUMBER = {6},
PAGES = {3317--3320},
URL = {http://www.techscience.com/CJU/v13n6/62438},
ISSN = {1488-5581},
ABSTRACT = {Bladder cancer is the fifth most common cancer in the
Western world and is on the rise. Most patients present
with superficial disease and are treated by transurethral
resection of bladder tumor. More than half of these
patients experience recurrence with about 20%
progressing to muscle invasive disease. Intravesical
chemotherapy has been shown to decrease the risk of
recurrence of bladder cancer. Mitomycin C has emerged
as a major agent for an immediate post-resection
intravesical instillation. This article reviews the
literature on the mode of action, rationale for immediate
adjuvant treatment with mitomycin C and adverse effects
associated with its use.},
DOI = {}
}